The Fort Worth Press - enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium

USD -
AED 3.672503
AFN 64.502706
ALL 82.158918
AMD 358.939509
ANG 1.790403
AOA 916.999961
ARS 1564.869898
AUD 1.50179
AWG 1.8
AZN 1.688633
BAM 1.784033
BBD 2.019539
BDT 124.712665
BGN 1.77347
BHD 0.378367
BIF 3011.780588
BMD 1
BND 1.292991
BOB 11.787135
BRL 5.940185
BSD 1.002654
BTN 93.493996
BWP 14.163223
BYN 2.998481
BYR 19600
BZD 2.01662
CAD 1.432955
CDF 2280.000319
CHF 0.84195
CLF 0.025839
CLP 1016.940067
CNY 6.666651
CNH 6.682505
COP 3430.58
CRC 448.877578
CUC 1
CUP 24.064252
CVE 100.580597
CZK 22.30665
DJF 178.556769
DKK 6.819075
DOP 60.358117
DZD 137.187977
EGP 53.812701
ERN 15
ETB 164.575067
EUR 0.91228
FJD 2.293649
FKP 0.762556
GBP 0.763375
GEL 2.594978
GGP 0.762556
GHS 11.787081
GIP 0.762556
GMD 73.999836
GNF 8888.99024
GTQ 7.66589
GYD 209.71832
HKD 7.838535
HNL 26.953635
HRK 6.831965
HTG 131.457369
HUF 340.945963
IDR 18272
ILS 3.342375
IMP 0.762556
INR 92.64635
IQD 1520.092309
IRR 1937314.497456
ISK 124.990112
JEP 0.762556
JMD 158.691934
JOD 0.708992
JPY 158.834504
KES 130.059858
KGS 87.449752
KHR 4080.068959
KMF 448.999481
KPW 900.00035
KRW 1340.440142
KWD 0.31157
KYD 0.835644
KZT 451.435765
LAK 22592.768271
LBP 89796.128726
LKR 333.755975
LRD 168.449186
LSL 17.274601
LTL 2.95274
LVL 0.60489
LYD 6.489159
MAD 9.971905
MDL 18.399496
MGA 4527.086811
MKD 56.144879
MMK 2099.807194
MNT 3607.161117
MOP 8.102142
MRU 40.900654
MUR 46.779598
MVR 15.409777
MWK 1738.682283
MXN 19.0766
MYR 4.112797
MZN 63.910194
NAD 17.27405
NGN 1365.801385
NIO 36.896835
NOK 9.75524
NPR 149.590893
NZD 1.82111
OMR 0.384498
PAB 1.002755
PEN 3.42148
PGK 4.510668
PHP 63.807951
PKR 277.171369
PLN 4.06494
PYG 6286.657727
QAR 3.645038
RON 4.87978
RSD 107.340969
RUB 82.101465
RWF 1484.005145
SAR 3.751725
SBD 8.130619
SCR 13.808268
SDG 601.503576
SEK 10.220975
SGD 1.289855
SHP 0.760572
SLE 22.797771
SLL 20969.503664
SOS 573.031402
SRD 37.359641
STD 20697.981008
STN 22.348407
SVC 8.773306
SYP 13002.000337
SZL 17.270065
THB 33.942502
TJS 9.224798
TMT 3.51
TND 3.038261
TOP 2.40776
TRY 50.577797
TTD 6.803701
TWD 32.953898
TZS 2667.515002
UAH 45.169709
UGX 4246.158618
UYU 40.700724
UZS 12012.442077
VES 917.61775
VND 25801.5
VUV 121.154187
WST 2.823282
XAF 598.416608
XAG 0.023631
XAU 0.000279803242
XCD 2.70255
XCG 1.807054
XDR 0.707052
XOF 598.416608
XPF 108.786077
YER 236.549943
ZAR 17.49311
ZMK 9001.197733
ZMW 20.605862
ZWL 321.999592
SSP 5782.645223
MXV 2.138426
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium

enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium

Three-year follow-up data from the VenoValve pivotal trial shows sustained clinical improvement and continued patient benefit at 36 months compared to baseline, with statistically significant improvements in disease severity, leg pain, symptoms and quality of life

Company also highlights its next-generation, non-surgical enVVe system and remains on track to enroll the first subject in the TAVVE pivotal study by year-end 2026

Text size:

IRVINE, CA / ACCESS Newswire / November 20, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, will present three-year data from SAVVE, the U.S. pivotal study of the VenoValve® today at the 53rd Annual Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York City. The data, which will be presented by Dr. David Dexter of Sentara Vascular Specialists, shows sustained, statistically significant improvements in the revised Venous Clinical Severity Score (rVCSS), leg pain and quality-of-life measures in patients with severe chronic venous insufficiency (CVI). The presentation will also highlight enVVe®, the Company's next-generation, non-surgical transcatheter replacement venous valve.

Among the data being presented at VEITH are:

  • 5.8-point average improvement in disease severity, as measured by rVCSS, from baseline to 36 months.
  • 18-point and 19-point average improvements in venous disease-specific quality of life (VEINES-QOL) and symptoms (VEINES-Sym), respectively.

The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases, and a 5.8-point improvement represents a real difference in the daily lives of these patients. Improvement was observed as early as three months following implantation and was sustained through 36 months.

"Patients improved significantly after receiving the VenoValve, and this three-year data shows that those benefits have been sustained," said Robert Berman, Chief Executive Officer of enVVeno Medical. "Demonstrating the long-term viability of our replacement venous valve technology is critically important as we advance enVVe."

enVVe, the Company's next-generation, non-surgical replacement venous valve, builds on the clinical experience gained with VenoValve. Unlike VenoValve, which requires an open surgical procedure and an overnight hospital stay, enVVe is designed to be implanted in a less invasive procedure performed under light sedation, with patients expected to go home the same day.

enVVe will be evaluated in TAVVE (TrAnscatheter Venous Valve Endoprosthesis), a prospective, multicenter pivotal study that received FDA Investigational Device Exemption (IDE) authorization in April 2026. Part 1 of the TAVVE pivotal study will consist of up to 10 patients who will initially be monitored for safety. Following FDA review, the Company plans to proceed to Part 2 of the TAVVE pivotal study, which will evaluate regurgitant flow volume and rVCSS, along with other secondary endpoints. The Company remains on track to enroll the first patient in TAVVE by year-end 2026.

About the enVVe System

The investigational enVVe System is a transcatheter-delivered replacement venous valve designed to restore one-way blood flow in the deep veins of patients with chronic venous insufficiency. An estimated 3 million people in the U.S. suffer from severe deep venous insufficiency, and it remains one of the largest unmet needs in vascular medicine. As venous valves fail, patients often experience chronic pain, swelling, skin changes, recurrent venous leg ulcers and declining quality of life.

Despite the significant burden of deep venous insufficiency, treatment options remain limited and are primarily focused on managing symptoms through compression therapy and wound care rather than addressing the underlying cause: dysfunctional venous valves. The enVVe System is being developed to address this critical treatment gap by helping restore proper directional blood flow to the deep venous system.

About the SAVVE Study

The SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) study is a prospective, single-arm, multicenter U.S. pivotal clinical study evaluating VenoValve in 75 patients with severe chronic venous insufficiency due to deep venous reflux across 21 U.S. clinical centers. The study includes patients with CEAP clinical classifications C4b through C6 and evaluates changes in disease severity, pain, quality of life, symptoms, venous ulcer area and device patency, with follow-up extending to five years.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
[email protected]
(908) 824-0775

SOURCE: enVVeno Medical Corporation



View the original press release on ACCESS Newswire

W.Knight--TFWP